CoChat
Sign Up
Cited by 36

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma

Haltom, Amanda R., Hassen, Wafa E., Hensel, Janine, Kim, Jiha, Sugimoto, Hikaru, Li, Bingrui, McAndrews, Kathleen M., Conner, Meagan R., Kirtley, Michelle L., Luo, Xin, Xie, Bingqing, Volpert, Olga V., Olalekan, Susan, Maltsev, Natalia, Basu, Anindita, LeBleu, Valerie S., Kalluri, Raghu·2022·Extracellular Vesicle
DOI 10.1016/j.vesic.2022.100014PMC PMC10373511
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vesic.2022.100014

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 52

  1. Arvanitis, 2020, The blood–brain barrier and blood-tumour barrier in brain tumours and metastases, Nat Rev Cancer, 20, 26, 10.1038/s41568-019-0205-x · DOI
  2. Patel, 2014, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science, 344, 1396, 10.1126/science.1254257 · DOI · Paper page
  3. Neftel, 2019, An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell, 178, 835, 10.1016/j.cell.2019.06.024 · DOI · Paper page
  4. Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 9, 157, 10.1016/j.ccr.2006.02.019 · DOI
  5. Wang, 2019, The phenotypes of proliferating glioblastoma cells reside on a single axis of variation, Cancer Discov, 9, 1708, 10.1158/2159-8290.CD-19-0329 · DOI
  6. Minata, 2019, Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation, Cell Rep, 26, 1893, 10.1016/j.celrep.2019.01.076 · DOI
  7. Wang, 2017, Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment, Cancer Cell, 32, 42, 10.1016/j.ccell.2017.06.003 · DOI
  8. Bhat, 2013, Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma, Cancer Cell, 24, 331, 10.1016/j.ccr.2013.08.001 · DOI
  9. Halliday, 2014, In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift, Proc Natl Acad Sci USA, 111, 5248, 10.1073/pnas.1321014111 · DOI
  10. Lathia, 2015, Cancer stem cells in glioblastoma, Genes Dev, 29, 1203, 10.1101/gad.261982.115 · DOI · Paper page
  11. Zaytseva, 2020, MYC in brain development and cancer, Int J Mol Sci, 21, 10.3390/ijms21207742 · DOI
  12. Ashrafizadeh, 2021, C-Myc signaling pathway in treatment and prevention of brain tumors, Curr Cancer Drug Targets, 21, 2, 10.2174/1568009620666201016121005 · DOI
  13. Wang, 2020, Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC, Biochem Biophys Res Commun, 533, 368, 10.1016/j.bbrc.2020.09.008 · DOI
  14. Lee, 2021, Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc, Cell Death Dis, 12, 89, 10.1038/s41419-020-03380-2 · DOI
  15. Bhaduri, 2020, Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma, Cell Stem Cell, 26, 48, 10.1016/j.stem.2019.11.015 · DOI · Paper page
  16. Annibali, 2014, Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis, Nature Commun, 5, 4632, 10.1038/ncomms5632 · DOI
  17. Li, 2020, Protective effect of c-Myc/Rab7a signal pathway in glioblastoma cells under hypoxia, Ann Transl Med, 8, 283, 10.21037/atm.2020.02.173 · DOI
  18. Soucek, 2008, Modelling Myc inhibition as a cancer therapy, Nature, 455, 679, 10.1038/nature07260 · DOI
  19. Whitfield, 2021, The long journey to bring a Myc inhibitor to the clinic, J Cell Biol, 220, 10.1083/jcb.202103090 · DOI
  20. Wilson, 2004, c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation, Genes Dev, 18, 2747, 10.1101/gad.313104 · DOI · Paper page
  21. Yang, 2014, Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability, Febs J, 281, 802, 10.1111/febs.12625 · DOI
  22. Zhang, 2020, AGO2 mediates MYC mRNA stability in hepatocellular carcinoma, Mol Cancer Res, 18, 612, 10.1158/1541-7786.MCR-19-0805 · DOI
  23. Visvanathan, 2019, N6-methyladenosine landscape of glioma stem-like cells: METTL3 is essential for the expression of actively transcribed genes and sustenance of the oncogenic signaling, Genes (Basel), 10, 10.3390/genes10020141 · DOI
  24. Wolf, 2020, Targeting MYC proteins for tumor therapy, Annu Rev Cancer Biol, 4, 61, 10.1146/annurev-cancerbio-030518-055826 · DOI
  25. Madden, 2021, Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc, Mol Cancer, 20, 3, 10.1186/s12943-020-01291-6 · DOI
  26. Masso-Valles, 2020, Blocking Myc to treat cancer: Reflecting on two decades of omomyc, Cells, 9, 10.3390/cells9040883 · DOI
  27. Sklar, 1991, Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells, Mol Cell Biol, 11, 3699
  28. Devi, 2005, In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors, Clin Cancer Res, 11, 3930, 10.1158/1078-0432.CCR-04-2091 · DOI
  29. Habib, 2020, Anti-c-myc RNAi-based onconanotherapeutics, Biomedicines, 8, 10.3390/biomedicines8120612 · DOI · Paper page
  30. Kalluri, 2020, The biology, function, and biomedical applications of exosomes, Science, 367, 10.1126/science.aau6977 · DOI · Paper page
  31. Kamerkar, 2017, Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer, Nature, 546, 498, 10.1038/nature22341 · DOI · Paper page
  32. Mendt, 2018, Generation and testing of clinical-grade exosomes for pancreatic cancer, JCI Insight, 3, 10.1172/jci.insight.99263 · DOI
  33. McAndrews, 2021, Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity, J Biol Chem, 296, 10.1016/j.jbc.2021.100523 · DOI
  34. Perocheau, 2021, Clinical applications for exosomes: Are we there yet?, Br J Pharmacol, 178, 2375, 10.1111/bph.15432 · DOI · Paper page
  35. Perets, 2018, Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice, Mol Autism, 9, 57, 10.1186/s13229-018-0240-6 · DOI
  36. Meyer, 2008, Reflecting on 25 years with MYC, Nat Rev Cancer, 8, 976, 10.1038/nrc2231 · DOI · Paper page
  37. Wu, 2019, Advantages of single-nucleus over single-cell RNA sequencing of adult kidney: Rare cell types and novel cell states revealed in fibrosis, J Am Soc Nephrol, 30, 23, 10.1681/ASN.2018090912 · DOI · Paper page
  38. Basile, 2021, Using single-nucleus RNA-sequencing to interrogate transcriptomic profiles of archived human pancreatic islets, Genome Med, 13, 128, 10.1186/s13073-021-00941-8 · DOI
  39. Tirosh, 2016, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, Science, 352, 189, 10.1126/science.aad0501 · DOI · Paper page
  40. Barron, 2016, Identifying and removing the cell-cycle effect from single-cell RNA-sequencing data, Sci Rep, 6, 33892, 10.1038/srep33892 · DOI
  41. Kim, 2021, Perspective of mesenchymal transformation in glioblastoma, Acta Neuropathol Commun, 9, 50, 10.1186/s40478-021-01151-4 · DOI
  42. Fedele, 2019, Proneural-mesenchymal transition: Phenotypic plasticity to acquire multitherapy resistance in glioblastoma, Int J Mol Sci, 20, 10.3390/ijms20112746 · DOI
  43. Behnan, 2019, The landscape of the mesenchymal signature in brain tumours, Brain, 142, 847, 10.1093/brain/awz044 · DOI
  44. Moss, 2021, Intranasal delivery of exosomes from human adipose derived stem cells at forty-eight hours post injury reduces motor and cognitive impairments following traumatic brain injury, Neurochem Int, 150, 10.1016/j.neuint.2021.105173 · DOI
  45. Jain, 2002, Sustained loss of a neoplastic phenotype by brief inactivation of MYC, Science, 297, 102, 10.1126/science.1071489 · DOI
  46. Fedchenko, 2014, Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review, Diagn Pathol, 9, 221, 10.1186/s13000-014-0221-9 · DOI
  47. DeLuca, 2012, RNA-SeQC: RNA-seq metrics for quality control and process optimization, Bioinformatics, 28, 1530, 10.1093/bioinformatics/bts196 · DOI · Paper page
  48. Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
  49. Korsunsky, 2019, Fast, sensitive and accurate integration of single-cell data with harmony, Nature Methods, 16, 1289, 10.1038/s41592-019-0619-0 · DOI · Paper page
  50. van Dijk, 2018, Recovering gene interactions from single-cell data using data diffusion, Cell, 174, 716, 10.1016/j.cell.2018.05.061 · DOI · Paper page
  51. Hao, 2021, Integrated analysis of multimodal single-cell data, Cell, 184, 3573, 10.1016/j.cell.2021.04.048 · DOI · Paper page
  52. Yu, 2012, Clusterprofiler: an r package for comparing biological themes among gene clusters, Omics, 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Haltom, A. R., Hassen, W. E., Hensel, J., Kim, J., Sugimoto, H., Li, B., McAndrews, K. M., Conner, M. R., Kirtley, M. L., Luo, X., Xie, B., Volpert, O. V., Olalekan, S., Maltsev, N., Basu, A., LeBleu, V. S., & Kalluri, R.
Venue
Extracellular Vesicle
Publisher
Elsevier BV
Published
2022-12
Volume
1
Pages
100014
ISSN
2773-0417
DOI
10.1016/j.vesic.2022.100014
PMC
PMC10373511
Cited by
36
References
11
Language
en
Licence
Funders
  • Musella Foundation For Brain Tumor Research and Information
  • National Cancer Institute (P30CA016672)
  • University of Texas MD Anderson Cancer Center
  • National Institutes of Health (R35CA263815)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review